Syntekabio will present its cutting-edge AI drug discovery platforms, DeepMatcher® and NEO-ARS™, at the UKC 2022 on August 19 in Arlington, Virginia. The conference promotes collaborative opportunities for professionals from the U.S. and Korea in science and technology, aimed at enhancing business relations. Founded in 2009, Syntekabio uses AI to revolutionize drug development globally.
Syntekabio, a leader in AI-driven drug discovery, will showcase its advanced cloud platforms, DeepMatcher® and NEO-ARS™, during the US-Korea Conference (UKC) 2022 on August 19 in Arlington, Virginia. These platforms are set to launch this September and represent a significant innovation in the pharmaceutical industry. The event aims to foster collaboration and networking among American and Korean professionals in science and technology.
The US-Korea Conference (UKC) serves as a platform for promoting cooperation between U.S. and Korean experts in various fields, including science and technology. It encourages cross-border business development while offering budding entrepreneurs chances to engage with influential investors. Syntekabio, headquartered in South Korea since 2009, integrates AI and big data to enhance drug discovery and development, striving to create medicines that adhere to global standards.
In conclusion, Syntekabio is set to make a significant impact at the UKC 2022 by introducing its groundbreaking AI drug discovery platforms, DeepMatcher® and NEO-ARS™. The conference presents a unique opportunity for knowledge exchange and the establishment of industry connections between U.S. and Korean professionals. Syntekabio’s commitment to innovation underscores its role in transforming global healthcare.
Original Source: www.globenewswire.com